Wells Fargo analyst Stephen Baxter raised the firm’s price target on CVS Health (CVS) to $103 from $102 and keeps an Overweight rating on the shares. The firm is constructive on Q1 results and optionality for positive earnings revisions through 2026 given conservative approach to Health Care Benefits guidance. Wells is increasing estimates by net favorable PYD and stronger PCW performance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Analyst Reaffirms Buy on CVS After Strong Q1, Raises EPS Outlook and Nudges Price Target to $103 for Further Upside
- CVS Health Earnings Call Highlights Growth And Risks
- Private Markets: Musk tightens grip at SpaceX, Sierra hits $15B valuation
- CVS Health price target raised to $92 from $88 at Deutsche Bank
- CVS Health price target raised to $107 from $90 at RBC Capital